SBS says investors can join Capricor securities class action over Deramiocel claims
Schall, Brown & Schwartz LLP says it is reminding investors about a securities class action against Capricor Therapeutics over alleged statements about Deramiocel and an FDA review of the company’s biologics license application.
Schall, Brown & Schwartz LLP says it is reminding investors about a securities class action against Capricor Therapeutics Inc. over alleged violations of federal securities laws tied to statements about Deramiocel and the Food and Drug Administration’s review of the company’s biologics license application.
The firm said the case concerns claims that Capricor made false and misleading statements to the market, changed the statistical analysis plan used to assess clinical data for Deramiocel, and did so even though the FDA had not agreed to changes from the pre-specified plan before the BLA was resubmitted. The release also says the company faced a significant risk that the FDA would not approve the BLA because of a lack of sufficient evidence of effectiveness.
The release says the lawsuit involves investors who bought Capricor shares during the stated class period and alleges damages after the market learned the truth. It also says the class has not yet been certified, so the claims remain allegations.
According to the release, the lawsuit alleges violations of Section 10(b), Section 20(a) and SEC Rule 10b-5 under the Securities Exchange Act of 1934. The stated class period runs from Dec. 17, 2025, to July 26, 2026. The release identifies Capricor Therapeutics as a Nasdaq-listed company under the ticker CAPR.
Schall, Brown & Schwartz described itself in the release as a national shareholder rights litigation firm. The firm said shareholders who purchased CAPR shares during the class period may contact it about possible lead plaintiff appointments, and it said lead plaintiff status is not required to recover in the case.
The release includes contact information for Brian Schall and David Schwartz, along with the firm’s Los Angeles address, phone number, website and email. It also says that until certification occurs, investors are not represented by an attorney and may choose absent class member status if they take no action.
What happens next will depend on the progress of the case and any court action on class certification and lead plaintiff issues. The release does not say when any hearing or ruling is due.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
Comments ()